Contrast agent – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:59 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Contrast agent – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Iohexol Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-iohexol-market-2021-2025/ Mon, 19 Jul 2021 02:43:41 +0000 https://www.cri-report.com/?post_type=product&p=13249 In 2020, due to the impact of COVID-19 on the hospital's overall diagnosis and treatment services, its sales value of Iohexol in the Chinese market decreased to CNY691 million, a year-on-year decrease of 13.53%.

The post Investigation Report on China’s Iohexol Market 2021-2025 first appeared on CRI Report.

]]> Iohexol is a non-ionic X-ray contrast agent. Iohexol injection is suitable for intravascular and intracavitary injections in adults and children. In clinical angiography (cerebrovascular angiography, coronary angiography, peripheral and visceral angiography, ventricle angiography), CT-enhanced imaging of the head and body , Intravenous urography (IVP), arthrography, endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), hernia or fistula angiography, gastrointestinal angiography, “T “Pipeline radiography and so on. Iohexol was developed by Nycomed and was approved to enter the Chinese market in 1997. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are several suppliers in the Chinese Iohexol market by 2020, of which Yangtze River Pharmaceutical Group Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Iohexol in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the hospital’s overall diagnosis and treatment services, its sales value of Iohexol in the Chinese market decreased to CNY691 million, a year-on-year decrease of 13.53%. The CAGR of Iohexol sales value in the Chinese market from 2016 to 2020 is 0.45%.

CRI expects that with the relief of COVID-19, the sales of Iohexol in the Chinese market will have a restorative growth from 2021 to 2025. With the popularization of medical services in China and the advancement of medical technology, the demand for iodine and a non-ionic X-ray contrast agent in Chinese medical industry has gradually expanded, and sales value are expected to continue to grow from 2021 to 2025.

 

Topics Covered:

  • -The impact of COVID-19 on China’s Iohexol market
  • – Sales value of China’s Iohexol 2016-2020
  • – Competitive landscape of China’s Iohexol market
  • – Prices of Iohexol in China
  • – Prices of Iohexol in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Iohexol market
  • – Prospect of China’s Iohexol market from 2021 to 2025

The post Investigation Report on China’s Iohexol Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Iodixanol Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-iodixanol-market-2021-2025/ Fri, 23 Apr 2021 13:02:59 +0000 https://www.cri-report.com/?post_type=product&p=11192 According to CRI's market research, the sales value of Iodixanol in the Chinese market has increased from 2016 to 2020. Th sales value of Iodixanol in China reached approximately CNY1.49 billion in 2020, with an increase of 1.52% YoY.

The post Investigation Report on China’s Iodixanol Market 2021-2025 first appeared on CRI Report.

]]> Iodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma. It is used for cardiovascular angiography, cerebrovascular angiography, abdominal angiography, and so on. Iodixanol was developed by Nycomed, a Norwegian company, naming VISIPAQUE (Nycomed was acquired by GE after the merge with Amersham, and become GE Healthcare). In 2001, Iodixanol entered the Chinese market. Currently, besides GE Healthcare, the other main manufacturers in China are Jiangsu Hengrui Medicine, Yangtze River Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Beijing Beilu Pharmaceutical.

According to CRI’s market research, the sales value of Iodixanol in the Chinese market has increased from 2016 to 2020. Th sales value of Iodixanol in China reached approximately CNY1.49 billion in 2020, with an increase of 1.52% YoY. The growth rate slowed down last year is because the COVID-19 epidemic causes a reduction in the number of operations in hospitals, which influences the sales of Iodixanol. The CAGR of sales value of Iodixanol in China is 27% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved, the sales of Iodixanol will have a recovery growth from 2021 to 2025. In addition, the sales of Iodixanol will also increase due to the market expansion. According to the research, the sales of contrast agents are directly related to the holding volume of CT and MRI. The holding volume in China is much less than that in developed countries. For example, the holding volume of CT for a million people in China is 1/2 of that in the U.S., and 1/5 of that in Japan. Therefore, the number of equipment still has the potential to increase, which will lead the contrast agent market to expand. Iodixanol, as one of the most popular contrast agents, will continue to grow in the short term.

Topics Covered:
-The impact of COVID-19 on China’s Iodixanol market
– Sales value and volume of China’s Iodixanol 2016-2020
– Competitive landscape of China’s Iodixanol market
– Prices of Iodixanol in China
– Prices of Iodixanol in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Iodixanol market
– Prospect of China’s Iodixanol market from 2021 to 2025

The post Investigation Report on China’s Iodixanol Market 2021-2025 first appeared on CRI Report.

]]>